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Introduction 
Canavan’s disease is a fatal illness that begins early in infancy and the major 
manifestation is white matter dysmyelination that are delineated as spongy 
degenerations. Initially, Canavan’s described was described by Canavan in 1931 
Abstract
Objective 
Canavan’s disease is a lethal illness caused by a single gene mutation that is 
inherited as an autosomal recessive pattern. It has many different clinical features 
especially in the non-Ashkenazi Jewish population.
Material & Methods
45 patients were referred to the Pediatric Neurology Department of Mofid 
Children’s Hospital in Tehran-Iran from 2010–2014 with a chief complaint 
of neuro developmental delays, seizures, and neuroimaging findings of 
leukodystrophy were included in this study. Magnetic Resonance Spectrometry 
(MRS) and neuro metabolic assessment from a referral laboratory in Germany 
confirmed that 17 patients had Canavan’s disease. 
Results
Visual impairment, seizure, hypotonia, neuro developmental arrest, and 
macrocephaly were the most consistent findings in the patients in this study. 
Assessments of neuro developmental status revealed that 13 (76%) patients had 
neuro developmental delays and 4 (24%) patients had normal neuro development 
until 18 months of age and then their neuro developmental milestones regressed. 
In this study, 100% of cases had macrocephalia and 76% of these patients had 
visual impairment. A history of seizures was positive in 8 (47%) patients and 
began around 3 months of age with the most common type of seizure was tonic 
spasm. EEGs were abnormal in all epileptic patients. In ten of the infantile 
group, we did not detect elevated level of N-acetylaspartic acid (NAA) in serum 
and urine. However, the MRS showed typical findings for Canavan’s disease 
(peaks of N-acetylaspartic acid).
Conclusion 
We suggest using MRS to detect N-acetylaspartic acid as an acceptable method 
for the diagnosis of Canavan’s disease in infants even with normal serum and 
urine N-acetylaspartic acid levels.
Keywords: Canavan’s disease; diagnosis. N- Acetylaspartic acid; Magnetic 
Resonance Spectrometry
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chromatography in urine showed increased metabolites 
except N-acetylaspartic acid, and the MRS detected 
material sediment of other than NAA or borderline results. 
Canavan’s disease was confirmed in 17 patients from 
clinical manifestation, neuroimaging findings, elevated 
level of NAA in MRS, and neuro metabolic assessments 
from a referral laboratory in Germany. 
Patient information
Patient information such as age, gender, past medical 
history, developmental status, general appearance, 
clinical, and neuroimaging findings were collected.
Management
Management included control of seizures, treatment for 
infection (if present), and follow up of growth index by 
the best feeding drive.
Data analysis
The data was analyzed using descriptive methods and no 
statistical testing was applied. This is an observational 
study.
Ethical approval 
Institutional ethical approval to conduct this study was 
obtained from the Pediatric Neurology Research Center of 
Shahid Beheshti University of Medical Sciences, Tehran, 
Iran. All parents signed a written consent for participation 
in the study.
Results
Patient information
Canavan’s disease was confirmed in 17 patients (10 males 
and 7 females).
The earliest case was diagnosed in a 5-month-old patient 
and the latest case was diagnosed in a 5.5-year-old patient. 
The median age of presentation of symptoms was 8 
months and the median age of patients at assessment time 
was 31 months. A total of 85% of patients (14 patients) 
were offspring of consanguineous marriages. Nine 
patients had parents who were first cousins and in another 
5 patients, their parents were second cousins. A family 
history of Canavan’s disease was positive for 2 patients.
Clinical results
A prenatal history of patients showed there was a history 
of preeclampsia in one patient and history of gestational 
diabetes in another patient. Prenatal history revealed 
that one patient was preterm with a gestational age of 32 
weeks, one patient was post term with gestational age of 
and is now known as Canavan’s disease. The striking 
features of Canavan’s disease is a failure to attain 
neuro developmental milestones, abnormally decreased 
muscular tone, increased head circumference, seizure, 
atrophy of the optic nerve, and early death (1-6). 
Canavan’s disease inherited with an autosomal recessive 
pattern and is most common in the Ashkenazi Jewish 
community but there are other populations with different 
ethnic backgrounds who get this disease. Canavan’s 
disease is caused by a mutation in the gene that encodes 
the aspartoacylase enzyme. This enzymes main role is 
converting N-acetylaspartic acid to aspartate and acetate 
in the brain. 
Cloning the gene that is responsible for aspartoacylase 
enzyme production has lead to finding mutations that 
cause Canavan’s disease. There are many known 
mutations and some of them are more common to 
specific ethnic groups. 
When converting the N-acetylaspartic acid is blocked 
because of aspartoacylase enzyme deficiency, then 
N-acetylaspartic acid accumulates in the white matter and 
complicates normal development (7-12). 
The exact pathophysiology of Canavan’s disease is not 
elucidated but there are some interesting hypotheses that 
myelin breakdown can be the main cause of consequent 
devastating events. 
Management of the disease is based on supporting 
nutrition and controlling seizures and infections but gene 
therapy is a promising new horizon in treatment and many 
investigators try to transfer normal gene sequences in the 
patient’s genome. This study evaluates the clinical features 
of Canavan’s disease and elucidates the best approach for 
a correct diagnosis (13-20).
Materials & Methods
Participants and diagnosis
In this study, 45 patients (aged from 5–66 months) 
referred to the Pediatric Neurology Department of Mofid 
Children’s Hospital in Tehran-Iran (2010–2014) with a 
chief complaint of neuro developmental delay, seizures, 
and neuroimaging findings of leukodystrophy were 
enrolled in our study. 
The exclusion criteria was patients who had 
leukodystrophy in their brain Magnetic resonance Imaging 
(MRI), but Tandem mass spectrometry in serum, gas 
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41 weeks, and others were term with normal weight and 
head circumference at birth. At neonatal period, 6 (35%) 
patients had jaundice that was treated with phototherapy. 
The patient who was delivered prematurely because of 
preeclampsia was admitted into the neonatal intensive 
care unit for 11 days. Congenital anomalies were not 
detected in any newborn babies at birth. Assessments of 
patients neuro developmental status, revealed 13 (76%) 
patients had neuro developmental arrest and 6 (24%) had 
normal neuro developmental milestones until 18 months 
of age and then they showed regression.
A history of seizure was positive in 8 (47%) patients and 
began around 3 months of age and the most common type 
of seizure was a tonic spasm. Three patients had drug 
resistant epilepsy. A neurological examination showed 
that 2 patients had ataxia, 2 had tremors, and 3 had severe 
dystonia. 11 (64%) patients had spasticity with increased 
deep tendon reflex. Increased deep tendon reflex and 
spasticity was more commonly observed in patients who 
were more than 1 year old. On the other hand, the deep 
tendons reflex was normal in 6 (36%) infant patients that 
all of them showed hypotonia. Ophthalmic examination 
revealed visual impairment in 41% of patients. Between 
7 (41%) patients had impaired fix and follow, 6 (35%) 
patients were blind with optic atrophy from the 
Fundoscopic examination. Not all patients had a history 
of macrocephalia but all of patients had macrocephalia at 
5 months old (above 95% percentile).
Based on the growth index assessment, eleven patients 
had failure to thrive (between 3–10 percentile). A follow-
up for all patients showed intellectual disabilities. One 
patient had a sibling with Canavan’s disease as well. 
There was no certain point in other physical examinations, 
such as hair and skin, face, chest, and abdomen.
Para clinical results
From the lab data, one patient had transitory increased 
levels of AST and ALT; and metabolic acidosis was not 
seen in patients. Electroencephalography (EEG) in 8 
(47%) patients with seizures was abnormal with no special 
patterns. The EMG-NCV study was normal in all patients. 
A potential assessment of abnormal vision in the majority 
of patients was present. Serum amino acid levels examined 
by the tandem mass spectrometry method, venues blood 
gas analysis and levels of lactate, ammonia, and pyruvate 
were within normal limits. N-acetylaspartic acid (NAA)
levels in the serum of one patient was abnormally high 
but its concentration in urine of 6 (36%) patients was high 
(the levels of NAA in cases were in a range of 410–1050 
µmol/mol creatine; with control level of 41 µmol/mol 
creatine). A genetic study was done on two brothers who 
were 5 months and 4 years old and revealed a positive 
result for c.244–245 in the SA mutation was found.
Neuroimaging results
In all patients, the MRS revealed a high peak of 
N-acetylaspartic acid but normal urine N- acetylaspartic 
acid level was seen in 9 patients under one years of age 
(Fig 1).
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 Fig 1. Detection of the markedly elevated NAA peak on MR spectroscopic images in patients with Canavan’s disease 
as well as an increase in the NAA-to-cholin  ratio and the NAA-to-creatine ratio. These are considered indicative of 
Canavan’s disease given associated white matter abnormalities.
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This finding can be explained by the accumulation of 
N-acetylaspartic acid in the brain occurs before increasing 
its concentration in the urine. MRI in all patients showed 
subcortical-periventricular white matter leukodystrophy. 
However, in 3 (18%) patients, there was bilateral globus 
pallidus and thalamus signal changes. (Fig 2). 
Discussion
Michals and Matalon indicated that 117studied patients 
concluded the mean concentration of N-acetylaspartic 
acid in urine of patients with severe Canavan’s disease 
was 1440.5 ± 873.3 µmol/mmol creatine. 
They highlighted the elevation of N-acetylaspartic acid 
concentration in CSF and in the urine of patients but the 
concentration of NAA were similar to our study (21). 
Breitbach-Faller et al. indicated that brain ultrasonography 
of patients with Canavan’s disease and presence of white 
matter echogenicity (22).
Matalon et al in two separate studies about neuroimaging 
of Canavan’s disease concluded that CTs or MRIs in 
infancy period may interpreted as normal (23), but in older 
patients’ the prominent findings are symmetric diffuse 
cortical and subcortical white matter changes although 
cerebellar and brain stem involvement may be less 
commonly seen (24). These studies about neuroimaging 
findings also support our findings. To the best of our 
knowledge, there are limited studies (with small sample 
size) about using MRS in the literature. Our study has 
a significant number of patients identified from the use 
MRS of Canavan’s disease.
In conclusion, one of the interesting findings in our study 
was that psychomotor arrest in the first 6 months of age and 
primary hypotonia replaced by spasticity with age. Both of 
these findings can be clinical manifestations of Canavan’s 
disease and our study showed that MRI and MRS are 
valuable diagnostic evaluations of this disease. An MRI 
can show dysmyelination of subcortical–periventricular 
white matter and the MRS shows N-acetylaspartic acid 
accumulation in the brain that can be detected before 
increasing its concentration in the urine, which is suitable 
for infants when N-acetylaspartic acid cannot be found in 
the urine.
We suggest the use of MRS for early diagnosis of 
Canavan’s disease in infants when N-acetyl Aspartic acid 
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Fig 2. Canavan’s disease demonstrates bilateral symmetric T2 white matter hyperintensity including involvement of the 
subcortical arcuate fibers. This disease appears diffusely throughout the cerebral white matter and does not enhance in 
computed tomography (CT) or MR imaging, and demonstrates variable involvement of the basal ganglia and cerebellar 
white matter.
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in the early stages of disease cannot be found in the urine. 
The MRS can show the peak of N-acetyl Aspartic Acid in 
hyper signal region of the white matter.
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